Aprea Therapeutics Inc (APRE)
NASDAQ:APRE
APREAprea Therapeutics
$4.37
$0.02 (0.46%)

Aprea Therapeutics Stock Analysis & Ratings

Aprea Therapeutics Stock Analysis Overview

Smart Score
6
Neutral
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The Aprea Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart

APRE

APRE Stock Stats

Previous Close$4.35
Open$4.41
Bid4.14 x 600
Ask4.77 x 1
Today’s Range$4.2 - $4.435
52-Week Range$3.88 - $31.45
Volume1.50M
Average Volume2.75M
Market Cap$92.59M
Beta-0.02
P/E Ratio-1.7
EPS-2.55
Earnings DateAug 17, 2021

Company Description

Aprea Therapeutics Inc

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded in 2002 and is headquartered in Boston, MA.
Sector
Healthcare
Industry
Biotechnology
CEO
Christian Stanton Schade
Employees
17
Address
535 Boylston Street, Boston, MA, 02116, US

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

APRE FAQ

What was Aprea Therapeutics’s price range in the past 12 months?
Aprea Therapeutics lowest stock price was $3.88 and its highest was $31.45 in the past 12 months.
    What is Aprea Therapeutics’s market cap?
    Aprea Therapeutics’s market cap is $92.59M.
      What is Aprea Therapeutics’s price target?
      The average price target for Aprea Therapeutics is $7.67. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $10.00 ,the lowest forecast is $6.00. The average price target represents 75.51% Increase from the current price of $4.37.
        What do analysts say about Aprea Therapeutics?
        Aprea Therapeutics’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.
          When is Aprea Therapeutics’s upcoming earnings report date?
          Aprea Therapeutics’s upcoming earnings report date is Aug 17, 2021 which is in 21 days.
            How were Aprea Therapeutics’s earnings last quarter?
            Aprea Therapeutics released its earnings results on May 06, 2021. The company reported -$0.456 earnings per share for the quarter, beating the consensus estimate of -$0.492 by $0.036.
              Is Aprea Therapeutics overvalued?
              According to Wall Street analysts Aprea Therapeutics’s price is currently Undervalued.
                Does Aprea Therapeutics pay dividends?
                Aprea Therapeutics does not currently pay dividends.
                What is Aprea Therapeutics’s EPS estimate?
                Aprea Therapeutics’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Aprea Therapeutics have?
                Aprea Therapeutics has 21,190,000 shares outstanding.
                  What happened to Aprea Therapeutics’s price movement after its last earnings report?
                  Aprea Therapeutics reported an EPS of -$0.456 in its last earnings report, beating expectations of -$0.492. Following the earnings report the stock price went down -0.922%.
                    Which hedge fund is a major shareholder of Aprea Therapeutics?
                    Currently, no hedge funds are holding shares in APRE

                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis